Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective

Author:

Dawkins Hugh J.S.1,Draghia-Akli Ruxandra23,Lasko Paul4,Lau Lilian P.L.5,Jonker Anneliene H.5,Cutillo Christine M.6,Rath Ana57,Boycott Kym M.8,Baynam Gareth910,Lochmüller Hanns11,Kaufmann Petra6,Le Cam Yann12,Hivert Virginie12,Austin Christopher P.6,

Affiliation:

1. Office of Population Health Genomics; Public Health Division; Department of Health; Government of Western Australia; Perth Australia

2. Directorate General for Research and Innovation (DG RTD); European Commission; Brussels Belgium (until April 2017)

3. Merck & Co. Inc.; Upper Gwynedd Pennsylvania USA (from June 2017)

4. Department of Biology; McGill University; Montréal Canada

5. IRDiRC Scientific Secretariat; Inserm-US14, Rare Diseases Platform Paris France

6. National Center for Advancing Translational Sciences (NCATS); National Institutes of Health (NIH); Bethesda Maryland USA

7. Orphanet; Inserm-US14, Rare Diseases Platform Paris France

8. Children's Hospital of Eastern Ontario Research Institute; University of Ottawa; Ottawa Canada

9. Genetic Services of Western Australia; King Edward Memorial Hospital; Perth Australia

10. Western Australian Register of Developmental Anomalies; Perth Australia

11. Institute of Genetic Medicine; Newcastle University; Newcastle upon Tyne UK

12. EURORDIS-Rare Diseases Europe; Paris France

Funder

SUPPORT-IRDiRC

RD-Connect

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Reference60 articles.

1. Rare essentials: drugs for rare diseases as essential medicines;Stolk;Bull. World Health Organ.,2006

2. Prevalence and Incidence of Rare Diseases: Bibliographic Data , in Orphanet Report Series, Rare Diseases Collection (eds. Rath, A. & Nguengang-Wakap, S.) http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf 2016

3. Rare diseases, orphan drugs and their regulation: questions and misconceptions;Tambuyzer;Nat. Rev. Drug Discov.,2010

4. International cooperation to enable the diagnosis of all rare genetic diseases;Boycott;Am. J. Hum. Genet.,2017

5. Rare diseases and orphan drugs;Melnikova;Nat. Rev. Drug Discov.,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3